comparemela.com

Latest Breaking News On - Bridge biotherapeutics - Page 1 : comparemela.com

Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-207 in EGFR-Mutant NSCLC

Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis

Bridge Biotherapeutics to Present at the 2023 BIO International Convention

/PRNewswire/ Bridge Biotherapeutics Inc. (KQ288330), a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer,.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.